Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 7

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 7
---
 accounting firm for the year ending December 31, 2025, (3) approve, on a non-binding advisory basis, the executive compensation of our named executive officers; (4) approve an amendment to our 2017 Employee, Director and Consultant Equity Incentive Plan, to replenish the share pool for equity incentive grants and (5) act on any other business matters properly brought before the meeting.

More information is included in our proxy statement. Your vote is important to us. Whether you attend the Annual Meeting or not, please vote promptly and submit your proxy online, by telephone, or by following the instructions on the proxy card or voting instruction card.

#### A Bright Future
In 2025, we will continue to build on the pillars of long-term revenue growth and adjusted profitability that were part of our results in 2024. Our clinically differentiated products continue to deliver value in real-world clinical settings by enabling early detection and better treatment decisions for providers and their patients. Our modernized laboratory facilities and robust commercial engine are examples of where our investments in automation and advanced technology are yielding improved workflows, faster turnaround times, and reduced operating costs. With increasing expansion of use cases for molecular diagnostic testing and the adoption of precision medicine, we believe we are poised for both organic growth and market share gains in a dynamic industry.

Myriad Genetics will continue to grow under Sam Raha when he becomes our new President and Chief Executive Officer, on April 30, 2025. Since joining us in December 2023, Sam has played an integral role in shaping our long-term growth strategy. His deep background in the diagnostics industry and the leadership qualities he embodies will be crucial to the continued growth of Myriad Genetics and in creating long-term value for our stakeholders. Further, Mark Verratti’s promotion to Chief Operating Officer will leverage his extensive experience in the industry and at our company. Mark redefined and strengthened our commercial operations during his tenure as Chief Commercial Officer. Additionally, Brian Donnelly has been appointed as Chief Commercial Officer, bringing more than 20 years of experience in healthcare, diagnostics, and medical technology. In this role, he will strengthen our commercial execution and patient and customer centric focus. Under their leadership, Myriad Genetics is well positioned for the future.

We are confident in our path forward in 2025 and remain committed to advancing our mission, achieving our ambitious goals, and exceeding your expectations with dedication and determination.

Sincerely,

Paul J. Diaz

President and Chief Executive Officer

Myriad Genetics, Inc.

####